|
Market Closed -
Nyse
21:00:02 10/02/2026 GMT
|
5-day change
|
1st Jan Change
|
|
117.15 USD
|
-0.42%
|
 |
+1.13%
|
+11.30%
|
|
02-10 |
Merck & Co. Insider Sold Shares Worth $1,202,844, According to a Recent SEC Filing
|
MT
| |
02-10 |
FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, primary peritoneal carcinoma
|
RE
| |
02-10 |
Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating
|
MT
| |
02-10 |
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
|
CI
| |
02-09 |
Merck & Co. Insider Sold Shares Worth $14,485,690, According to a Recent SEC Filing
|
MT
| |
02-06 |
Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing
|
MT
| |
02-06 |
Merck & Co. Insider Sold Shares Worth $765,920, According to a Recent SEC Filing
|
MT
| |
02-06 |
Merck & Co. Insider Sold Shares Worth $4,557,025, According to a Recent SEC Filing
|
MT
| |
02-06 |
Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating
|
MT
| |
02-06 |
Health Rounds: Women who have had an HPV vaccine need fewer cervical cancer screenings
|
RE
| |
02-05 |
Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut
|
RE
| |
02-05 |
Merck veteran Perlmutter-led Eikon ?Therapeutics valued at $860 million in Nasdaq debut
|
RE
| |
02-05 |
Merck Says Health Canada Approves Enflonsia for Respiratory Syncytial Virus Prevention in Newborns, Infants
|
MT
| |
02-05 |
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
|
AQ
| |
02-05 |
Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants
|
CI
| |
02-05 |
Analyst recommendations: Corteva, Snap, Alphabet, Eli Lilly, PayPal, Qualcomm…
|  | |
02-05 |
Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO
|
RE
| |
02-04 |
Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says
|
MT
| |
02-04 |
Health Rounds: Cancer immunotherapies may be more effective given earlier in the day
|
RE
| |
02-04 |
Bernstein Adjusts Price Target on Merck to $100 From $95, Maintains Market Perform Rating
|
MT
| |
02-04 |
Leerink Partners Adjusts Price Target on Merck to $128 From $124, Maintains Outperform Rating
|
MT
| |
02-04 |
Goldman Sachs Adjusts Price Target on Merck to $133 From $120, Maintains Buy Rating
|
MT
| |
02-04 |
BMO Capital Adjusts Price Target on Merck & Co. to $135 From $130, Maintains Outperform Rating
|
MT
| |
02-04 |
Scotiabank Adjusts PT on Merck & Co. to $136 From $120, Maintains Sector Outperform Rating
|
MT
| |
02-04 |
Morgan Stanley Adjusts Price Target on Merck & Co. to $109 From $101, Maintains Equalweight Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
